Republicans favor expanding employer child care tax credit; providers skeptical
Republican lawmakers have filed a proposed bill expanding an existing state business development tax credit related to child care. Child care providers who want to see a permanent state investment in their work said the bill was an inadequate gesture.
The state's current business tax credit for child care applies only to capital expenditures for an employee child care program. The proposed bill would expand that to include other costs, including operating a child care program for employees, reimbursing employees for child care costs and other costs related to child care benefits.
'These changes will increase the number of available child care slots and provide more options for families,' wrote Sen. Howard Marklein (R-Spring Green) and Rep. Karen Hurd (R-Withee) in a memo seeking cosponsors. 'While not a silver bullet, these changes are another step in the right direction to address the child care issue in Wisconsin.'
Critics dismissed the measure as inadequate.
In a press release Rep. Randy Udell (D-Fitchburg) sent out after the Assembly's floor session Tuesday, he noted that last week the Legislature's Joint Finance Committee 'shot down 612 budget items including $480 million in childcare funding, and they proposed a childcare tax credit in its place that would benefit corporations instead of childcare providers under threat of closure.'
Shawn Phetteplace, national campaigns director for Main Street Alliance, sent a memo to lawmakers Tuesday also dismissing the proposal.
'Providing a 15% refundable business tax credit for businesses providing child care benefits will not appreciably increase access to child care for Wisconsin workers,' Phetteplace wrote. 'It will simply be another tax break for large corporations. A similar credit exists at the federal level, the 45F credit, which is widely regarded as not achieving the goal of increasing affordability and accessibility to childcare for employees.'
Corrine Hendrickson, co-founder of Wisconsin Early Childhood Action Needed (WECAN), said at a Capitol rally Tuesday she would like to meet with Marklein, who cochairs the finance committee, as well as Rep. Mark Born (R-Beaver Dam) the other cochair.
The business tax credit is refundable: The credit recipient receives the full value of the credit back from the state, even if it is more than what the recipient owes in taxes. Hendrickson criticized the lawmakers for 'refusing to do the same for our hard-working families with the child and dependent tax credit.'
The state's child and dependent care tax credit for families, which was expanded in legislation enacted in March 2024, is not refundable. That effectively makes the tax credit worth much more to people with higher incomes than to those with lower incomes, as the Wisconsin Examiner has previously reported.
'We are not going to accept anything more that will entrench the wealthy and well connected into our system of having success in life,' Hendrickson said.
Born issued a statement this week that declared Republicans were focusing on other alternatives to the proposal for $480 million in subsidies for child care providers.
'Legislative Republicans have consistently supported a targeted approach to helping families afford child care, build provider capacity, and support recruitment of child care professionals,' Born said. 'Parents are best equipped to make decisions about the needs of their children and Legislative Republicans are committed to providing parents with options, helping families directly make child care more affordable.'
Born said the Legislature spends 'almost $1 billion' for child care.
Hendrickson said that virtually all that money is from the federal government and simply passes through the state budget. Only about $24.4 million comes from the state as a required match.
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

16 minutes ago
Sen. Lindsey Graham says Trump ready to ‘crush' Russian economy if Putin avoids talks with Zelenskyy
WASHINGTON -- Republican Sen. Lindsey Graham said Tuesday that he believes President Donald Trump is prepared to 'crush' Russia's economy with a new wave of sanctions if Russian President Vladimir Putin refuses to meet with Ukrainian President Volodymyr Zelenskyy in the coming weeks. Graham, who spoke with Trump on Tuesday morning, has pushed the president for months to support his sweeping bipartisan sanctions bill that would impose steep tariffs on countries that are fueling Russia's invasion of Ukraine by buying its oil, gas, uranium, and other exports. The legislation has the backing of 85 senators, but Trump has yet to endorse it. Republican leaders have said they won't move without him. 'If we don't have this thing moving in the right direction by the time we get back, then I think that plan B needs to kick in,' Graham said in a phone interview with The Associated Press on Tuesday. The Senate, now away from Washington for the August recess, is scheduled to return in September. Graham's call with Trump came less than 24 hours after high-stakes meetings at the White House with Zelenskyy and several European leaders. Trump and the leaders emerged from those talks sounding optimistic, with the expectation being that a Putin and Zelenskyy sit-down will happen soon. Still, Trump's comments to Graham, one of his top congressional allies, mark the latest sign that pressure is building — not just on Putin, but on Trump as well. 'Trump believes that if Putin doesn't do his part, that he's going to have to crush his economy. Because you've got to mean what you say,' Graham told reporters in South Carolina on Tuesday. As Congress prepares to return to session in early September, the next few weeks could become a defining test of whether lawmakers and international allies are prepared to act on their own if Trump doesn't follow through. Connecticut Sen. Richard Blumenthal, the lead Democrat pushing the bill with Graham, says there is a 'lot of reason for skepticism and doubt' after the meetings with Trump, especially because Putin has not made any direct promises. He said the Russian leader has an incentive to play 'rope-a-dope' with Trump. 'The only way to bring Putin to the table is to show strength,' Blumenthal told the AP this week. 'What Putin understands is force and pressure.' Still, Republicans have shown little willingness to override Trump in his second term. They abruptly halted work on the sanctions bill before the August recess after Trump said the legislation may not be needed. Asked Tuesday in a phone interview whether the sanctions bill should be brought up even without Trump's support, Graham said, 'the best way to do it is with him.' 'There will come a point where if it's clear that Putin is not going to entertain peace, that President Trump will have to back up what he said he would do,' Graham said. 'And the best way to do it is have congressional blessing.' The legislation would impose tariffs of up to 500% on countries such as China and India, which together account for roughly 70% of Russia's energy trade. The framework has the support of many European leaders. Many of those same European leaders left the White House on Monday with a more hopeful tone. Zelenskyy called the meeting with Trump 'an important step toward ending this war.' German Chancellor Friedrich Merz said that his expectations 'were not just met, they were exceeded.' Still, little concrete progress was visible on the main obstacles to peace. That deadlock likely favors Putin, whose forces continue to make steady, if slow, progress on the ground in Ukraine. French President Emmanuel Macron told reporters after talks at the White House that Trump believes a deal with Putin is possible. But he said sanctions remain on the table if the process fails.
Yahoo
29 minutes ago
- Yahoo
Medtronic PLC (MDT) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Raised EPS Guidance
This article first appeared on GuruFocus. Revenue: $8.6 billion, grew 8.4% reported and 4.8% organic. Cardiovascular Growth: 7% growth, driven by nearly 50% growth in cardiac ablation solutions. Neuroscience Growth: 3% growth, with mid-single-digit growth in cranial and spinal technologies. Medsurge Growth: 2% growth, with high single-digit growth in advanced energy. Diabetes Growth: 8% growth, including 11% growth in international markets. Adjusted Gross Margin: 65.1%, down 80 basis points year over year. Adjusted Operating Margin: 23.6%. Adjusted EPS: $1.26, $0.03 above the midpoint of guidance. R&D Investment: Up 7.7%, 100 basis points ahead of revenue growth. Fiscal Year '26 Organic Revenue Growth Guidance: Approximately 5%. Fiscal Year '26 EPS Guidance: Raised to $5.60 to $5.66. Warning! GuruFocus has detected 7 Warning Signs with ODFJF. Release Date: August 19, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Medtronic PLC (NYSE:MDT) reported consistent mid-single-digit revenue growth, with EPS exceeding guidance. The cardiovascular segment showed strong performance, with nearly 50% growth in cardiac ablation solutions driven by innovative product rollouts. The company raised its EPS guidance for the full year, reflecting confidence in continued financial acceleration. Medtronic PLC (NYSE:MDT) is poised for growth in the second half of the fiscal year, with several product launches and market expansions planned. The planned separation of the diabetes business is expected to be EPS accretive and improve operating margins, enhancing shareholder value. Negative Points Neuroscience growth was below trend due to specialty therapies, though improvements are expected in subsequent quarters. The Medsurge segment grew only 2%, aligning with expectations but indicating slower growth compared to other segments. The diabetes segment faced challenges in the US market, with growth primarily driven by international sales. Gross margin decreased by 80 basis points year-over-year, impacted by business mix and manufacturing ramp-up costs. Tariffs are expected to have a negative impact of approximately $185 million for fiscal '26, though this is an improvement from previous estimates. Q & A Highlights Q: Can you provide an update on the CAS business and its impact on overall growth? A: Geoff Martha, CEO, explained that the CAS business is accelerating, with 72% growth in the US. The company is confident in its ability to accelerate growth over FY26, with new technologies and a strong pipeline expected to have an outsized impact on US growth. Thierry Pieton, CFO, added that the US growth was impacted by slower growth in certain areas, but expects improvement as new products ramp up. Q: What is the purpose of the new Board committees focused on growth and operations? A: Geoff Martha, CEO, stated that the committees will provide focus and support management, particularly in growth and operational performance. The committees will include new directors with deep medtech experience and will have more frequent interactions with management to drive focus and execution. Q: Is the $2 billion target for annual CAS sales achievable in fiscal '26? A: Geoff Martha, CEO, confirmed that the target of an additional $1 billion on top of the FY25 base is on track. While it might extend into FY27, the company is confident in achieving this near-term goal. Q: How will the new directors and committees impact capital allocation and EPS growth? A: Geoff Martha, CEO, emphasized that the company is entering a new chapter focused on value creation. This includes more M&A, portfolio optimization, and increased investment in growth drivers. The committees will help ensure these strategies are executed effectively. Q: Can you discuss the potential impact of renal denervation on Medtronic's growth profile? A: Geoff Martha, CEO, highlighted that renal denervation (RDN) is a significant growth opportunity, with a massive patient population. The company is investing in market development and expects RDN to be a major driver of growth, potentially becoming one of the largest product categories for Medtronic. Q: What is the status of the diabetes business separation and its impact on growth? A: Thierry Pieton, CFO, confirmed that the separation is on track, with completion expected within 15 months. The diabetes business is entering a strong innovation cycle, and the separation is expected to be a value-creating event for shareholders. Q: How is the Hugo robotic system performing in international markets, and what are the expectations for the US launch? A: Michael Marinaro, EVP, stated that Hugo is performing well in over 30 countries, with significant double-digit growth in current accounts. The system's modular design and partnership approach are key strengths. The company is preparing for the US launch, with FDA approval processes underway. Q: What are the growth prospects for Medtronic's slower-growing businesses? A: Geoff Martha, CEO, noted that several slower-growing businesses have specific growth accelerators, such as new products and market expansions. The company is focused on driving growth across all segments, with organic and inorganic strategies. For the complete transcript of the earnings call, please refer to the full earnings call transcript. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Washington Post
31 minutes ago
- Washington Post
Texas Capitol evacuated after shooting threat citing ‘political situation'
The Texas Capitol was evacuated late Tuesday in response to a shooting threat that forced people — including those protesting a Republican order for police to escort Democratic lawmakers to their homes — to leave the building.